You are leaving and being redirected to www.sanofi.us, our parent company, where all product inquiries are handled.

1-877-4MOZOBIL
(1-877-466-9624)

Educational Resources

Stem cell mobilization therapy and autologous transplantation are complex procedures. Learn more about these procedures and the potential use of Mozobil in autologous stem cell transplantation for patients with non-Hodgkin’s Lymphoma (NHL) or Multiple Myeloma (MM).

Review educational materials about Mozobil, use our glossary and link to credible information sources online.

Support Materials

Patient & Family Education Booklet (PDF)
This booklet is designed to provide you with information regarding the use of Mozobil (plerixafor injection) to mobilize stem cells and autologous hematopoietic stem cell transplantation (HSCT) to treat non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM).

Potential Questions to Ask Your Doctor (PDF)
Potential questions to ask your doctor about stem cell transplantation.

Preparing for an Autologous Transplant (PDF)
Learn more about the autologous stem cell transplant process with a step-by-step guide.

Education Videos for Patients

How does Mozobil Work?

Learn more about the mechanism of action of Mozobil.
Download Video

The Autologous Stem Cell Transplant Process

Understand the steps involved in an autologous stem cell transplant and the role of Mozobil + G-CSF for mobilization.
Download Video

Additional Support

Learn more about your disease, hematopoietic stem cell mobilization and autologous transplantation with these useful online resources.
Learn more

Questions to Ask Your Doctor

Prepare for your next appointment with our list of questions to ask your doctor.

Prepare for an Autologous Stem Cell Transplant

Learn more about the autologous stem cell transplant process and what to expect with our easy-to-follow step-by-step guide.

Download guide (PDF)

Indication

Mozobil (plerixafor injection) is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).

Important Safety Information

Mozobil is not intended for HSCT mobilization and collection in patients with leukemia.
Mozobil in combination with G-CSF increases circulating WBCs. Your WBC counts will be monitored.
Thrombocytopenia (a decrease in the number of platelets circulating in the blood) has been observed in patients receiving Mozobil. Your platelet counts will be monitored.
Cancer cells may be released from the bone marrow and subsequently collected along with your stem cells during apheresis. The potential effects of infusing cancer cells during your transplant have not been well-studied.
Your spleen may be examined if you experience pain in the left upper stomach area or left shoulder area as these may be signs of an enlarged or burst (ruptured) spleen.
Mozobil may harm the unborn child when administered to a pregnant woman. Scientific studies have shown that Mozobil caused harm to unborn animals. The safety of Mozobil in pregnant women has not been established in clinical trials. If you are of childbearing potential you should be advised to avoid becoming pregnant while receiving treatment with Mozobil. If this drug is used during pregnancy, or if you become pregnant while taking this drug, you should be apprised of the potential hazard to the unborn child.
The most common adverse reactions (occurring in greater than or equal to 10% of patients) during HSC mobilization and apheresis were: diarrhea (37%), nausea (34%), tiredness (fatigue) (27%), injection site reaction (34%), headache (22%), pain in your joints (arthralgia) (13%), dizziness (11%), and vomiting (10%).